What do systematic reviews say?

Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation

• Antipsychotic dose reduction compared to dose continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 719 participants
  Moderate

Summary of findings table ‐ Indicated prevention interventions vs control group

• Primary‐level and community worker interventions for the prevention of mental disorders and the promotion of… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1136 participants
  Very low
• Primary‐level and community worker interventions for the prevention of mental disorders and the promotion of… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 152 participants
  Very low

Summary of findings table ‐ Selective prevention interventions vs control group

• Primary‐level and community worker interventions for the prevention of mental disorders and the promotion of… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 115 participants
  Very low
• Primary‐level and community worker interventions for the prevention of mental disorders and the promotion of… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 229 participants
  Very low

Summary of findings: catgut implantation at acupoints vs valproate

• Acupuncture for epilepsy 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 294 participants
  Moderate

Summary of findings: needle acupuncture plus valproate vs valproate

• Acupuncture for epilepsy 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Low

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings: Picture Exchange Communication System (PECS) vs treatment

The review found no eligible studies for this question.

• Communication interventions for autism spectrum disorder in minimally verbal children 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dietary interventions vs placebo or other interventions

The review found no eligible studies for this question.

• Dietary modifications for infantile colic 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 53 participants
  Very low

Summary of findings table ‐ Promotion/universal prevention interventions vs control group

• Primary‐level and community worker interventions for the prevention of mental disorders and the promotion of… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 684 participants
  Very low
• Primary‐level and community worker interventions for the prevention of mental disorders and the promotion of… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 803 participants
  Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1139 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 204 participants
  Low